Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Major response to everolimus in melanoma with acquired imatinib resistance.

Major response to everolimus in melanoma with acquired imatinib resistance. J Clin Oncol. 2012 Feb 01; 30(4):e37-40.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.